Polatuzumab ELISA Kit (DW431028)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DW431028
Description	Polatuzumab ELISA Kit (DW431028) — Quantitative sandwich ELISA for Polatuzumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Sensibilité	0.156 μg/ml
Plage	0.31-5 μg/mL
Numéro d'accès	P40259
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	Polatuzumab
Noms alternatifs	ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumab vedotin-piiq, 1313206-42-6
Contexte	B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy).
Note	For Research Use Only.